The news flourishes with the failure of access to antibiotics in India

Doctors say it is a dark paradox.

On the one hand, antibiotics are excessive so as not to work, lead the resistance and nourish the appearance of highly deadly errors. On the other hand, people die because they cannot reach these life -saving medications.

A new study conducted by the research and development partnership in the field of non -profit international research and development (GARDP) in accessing antibiotics at approximately 1.5 million cases of negative gram -resistant infections (CRGN), including India, Brazil and South Africa. CRGN bacteria is antibiotic resistance in the last line – however, only 6.9 % of patients have received appropriate treatment in the countries that have been studied.

India carried the lion’s share of CRGN infections and treatment efforts, as it got 80 % of the full courses of the studied antibiotics but it managed Ticket In reports of Lancet Diseases Diseases Journal. (The entire drug path for antibiotics indicates the full group of doses the patient needs to take over a specific period for the treatment of infection completely.)

Common in water, food, the environment, the human intestine, and the negative gram bacteria causes inflammation of the urinary tract infections (UTIS), pneumonia and food poisoning.

They can pose a serious threat to both new and elderly iron. In particular, they are patients with hospitalization with weak immunity, and they often spread quickly in intensive care units and prove difficulty – and sometimes impossible – to treat them. It is difficult to treat negative bacterial infections that resist cacons, because these bacteria are resistant to some of the strongest antibiotics.

“These infections are a daily truth in all age groups,” says Dr. Abdel Ghaffour, Adviser to infectious Diseases at Apollo Hospital in the Indian city of Chennai. “We often see patients whose antibiotics do not work – and they die.”

The paradox is harsh. While the world is trying to curb excessive use of antibiotics, the parallel tragedy plays quietly in poor countries: people who die from treatment are treatment because appropriate drugs are far.

“For years, the dominant narration was that antibiotics are excessive, but the blatant reality is that many people with high drug resistance infections in low and medium -income countries do not get the antibiotics they need,” says Dr. Jennifer Cohen, global access director to reach this study.

The study studied eight intravenously emerging drugs against the antibiotic-resistant bacteria-starting from ancient antibiotics including cholesterin to the latest such as CEFTAZIDIME-AVIBACTAM. Among the few available medications, Tigecycline was the most widely used.

The researchers blame the treatment gap for the weak health systems and limited access to effective antibiotics.

For example, only 103,647 full treatment courses of TigeCYCLINE were purchased in eight countries – much less than 1.5 million patients they need. This great deficiency has highlighted the global response to drug -resistant infection.

What prevents patients with drug -resistant infections in India from obtaining appropriate antibiotics?

Doctors refer to multiple barriers – access to the appropriate health facility, obtain accurate diagnostic tests, and access to effective drugs. The cost is still a big obstacle, as many of these antibiotics are priced out of the reach of poor patients.

“Those who can withstand the costs of these antibiotics often excessively use them; those who cannot, do not get them at all.” “We need a system that guarantees access to the poor and prevents misuse by desire.”

To improve access, these medications should be more affordable. To prevent misuse, the strongest organization is the key.

“From an ideal point of view, every recipe for hospitalization must require a second recording – by an infection or microbiologist,” says Dr. Gavor. “Some hospitals do it, but most of them do not do it. With the right supervision, organizers can ensure this usual practice becomes.”

The researchers say that the link to the problem of misuse is, as the researchers say that both the most intelligent policies and the strongest guarantees are both necessary. But arrival alone will not solve the crisis – the new antibiotic pipeline dries. The decline in research and development in antibiotics – and the limited availability of current drugs – is a global issue.

India bear One of the heaviest in the world from the antimicrobial resistance (AMR), but it may also carry the key to fighting it – both at home or globally.

“India is also one of the largest markets for new antibiotics and can successfully defend the development and access of new antibiotics,” says Dr. Cohen. With a strong pharmaceutical base, the country appears as an AMR innovation center, from Promise new antibiotics To advanced diagnosis.

Dr. Cohen says that India can enhance its response to antibiotics by generating local data to better estimate needs and identifying gaps in the care course.

This would allow more targeted interventions to improve access to appropriate drugs.

Innovative models are already arising-Kerala state, for example, “Axis and Equalist Path” to support the lowest level facilities in managing serious infections. Researchers say coordinated or collected purchases through hospitals or countries can also reduce the cost of the latest antibiotics, as it appears in cancer drug programs.

Without accessing appropriate antibiotics, modern medicine begins to collapse – doctors risk losing the ability to safely perform surgery or treat complications in cancer patients or daily infections.

“As an infectious disease doctor, I see the right use as one part – but only one part of access,” says Dr. Gavor. “When we get new antibiotics, it is important to save them on the one hand – and save them to the appropriate patients.”

It is clear that the challenge is not only the use of antibiotics wisely, but to ensure that they reach those who need them more.